Accuracy Coverage Pricing Contact
Shire

Shire (SHP)

Shire is a leading UK pharmaceutical company. It's products include products include include Vyvanse, Adderall, XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, Vpriv, Firazyr and Dermagraft.

Fundamentals

Optimized Dividends

Annual Dividends

Year Amount Change
2006 3.74p
2007 4.36p 16.6%
2008 6.55p 50.2%
2009 7.21p 10.1%
2010 8.14p 12.9%
2011 9.48p 16.5%
2012 11.13p 17.4%
2013 12.12p 8.9%
2014 14.65p 20.9%
2015 18.01p 22.9%
2016 24.16p 34.1%
2017 25.1965p 4.3%
2018 Login required
2019 Login required
2020 Login required

Dividends

Ex-Div Date Pay Date Year Type Frequency Status Amount
08 Sep 2010 07 Oct 2010 2010 Interim Semiannually Paid 1.41p
09 Mar 2011 07 Apr 2011 2010 Final Semiannually Paid 6.73p
07 Sep 2011 06 Oct 2011 2011 Interim Semiannually Paid 1.52p
07 Mar 2012 12 Apr 2012 2011 Final Semiannually Paid 7.96p
05 Sep 2012 04 Oct 2012 2012 Interim Semiannually Paid 1.74p (2.73c)
06 Mar 2013 09 Apr 2013 2012 Final Semiannually Paid 9.39p (14.6c)
04 Sep 2013 03 Oct 2013 2013 Interim Semiannually Paid 1.95p (3c)
05 Mar 2014 08 Apr 2014 2013 Final Semiannually Paid 10.17p (16.93c)
03 Sep 2014 03 Oct 2014 2014 Interim Semiannually Paid 2.24p (3.83c)
12 Mar 2015 14 Apr 2015 2014 Final Semiannually Paid 12.41p (19.09c)
03 Sep 2015 02 Oct 2015 2015 Interim Semiannually Paid 2.69p (4.21c)
10 Mar 2016 12 Apr 2016 2015 Final Semiannually Paid 15.32p (22.16c)
08 Sep 2016 07 Oct 2016 2016 Interim Semiannually Paid 3.52p (4.63c)
09 Mar 2017 25 Apr 2017 2016 Final Semiannually Paid 20.64p (25.7c)
07 Sep 2017 20 Oct 2017 2017 Interim Semiannually Paid 3.863p (5.09c)
08 Mar 2018 24 Apr 2018 2017 Final Semiannually Paid 21.333p (29.79c)
06 Sep 2018 19 Oct 2018 2018 Interim Semiannually Paid 4.26p (5.6c)
Login Login 2018 Final Semiannually Forecast Login
Login Login 2019 Interim Semiannually Forecast Login
Login Login 2019 Final Semiannually Forecast Login
Login Login 2020 Interim Semiannually Forecast Login
Login Login 2020 Final Semiannually Forecast Login

Recent news articles

Investment Tools Limited
Investment Tools Limited
DIVIDEND

In respect of the six months ended December 31, 2014 the Board has resolved to
pay an interim dividend of 19.09 US cents per Ordinary Share (2013: 16.93 US
cents per Ordinary Share).

Dividend payments will be made in Pounds Sterling to holders of Ordinary
Shares and in US Dollars to holders of ADSs. A dividend of 12.51(1) pence per
Ordinary Share (2013: 10.21 pence) and 57.27 US cents per ADS (2013: 50.79 US
cents) will be paid on April 14, 2015 to shareholders on the register as at
the close of business on March 13, 2015.

Together with the first interim payment of 3.83 US cents per Ordinary Share
(2013: 3.00 US cents per Ordinary Share), this represents total dividends for
2014 of 22.92 US cents per Ordinary Share (2013: 19.93 US cents per Ordinary
Share), an increase of 15% in US Dollar terms.

Read more
Investment Tools Limited

EXECUTING OUR STRATEGY

- Further enhanced organic growth and improved operating margins

- Progression of our late stage pipeline addressing unmet needs including:

- Lifitegrast for dry eye disease and LDX for binge eating and major depressive disorders

- Continued but focused R&D investment in other development opportunities

- Focus on growth and value-driving business development

- Good progress integrating three divisions into a simplified `One Shire'
organization to create operating leverage, drive fast decisions and focus on growth-driving products

Flemming Ornskov, M.D., Chief Executive Officer, commented:

"We are pleased with our Q2 results, have made good progress and have returned to higher growth.

We're successfully executing our strategy, which is to grow by focusing on innovation-driven specialty products through both R&D and M&A. We've sharpened our focus on commercial excellence and we're enhancing our pipeline productivity. Our late Phase 3 projects lifitegrast and LDX for BED are progressing well and are programs in which we have increasing confidence.

Our strategy has been designed to deliver further enhanced growth. We anticipate delivering full year double digit Non GAAP earnings growth in 2013 and are confident in our ability to grow operating margins going forward."

Read more
Investment Tools Limited


Financial Highlights Full Year 2012

Product sales $4,407 million +12%
Product sales excluding ADDERALL XR $3,978 million +16%
Total revenues $4,681 million +10%

Non GAAP operating income $1,474 million +9%
US GAAP operating income $949 million -14%

Non GAAP diluted earnings per ADS $6.10 +14%
US GAAP diluted earnings per ADS $3.93 -13%

Non GAAP cash generation $1,637 million +18%
Non GAAP free cash flow $1,256 million +43%
US GAAP net cash provided by operating activities $1,383 million +29%


DIVIDEND

In respect of the six months ended December 31, 2012 the Board has resolved to
pay an interim dividend of 14.60 US cents per ordinary share (2011: 12.59 US
cents per ordinary share).

Dividend payments will be made in Pounds Sterling to ordinary shareholders and
in US Dollars to holders of ADSs. A dividend of 9.39 pence per ordinary share
(2011: 7.96 pence) and 43.80 US cents per ADS (2011: 37.77 US cents) will be
paid on April 9, 2013 to shareholders on the register as at the close of
business on March 8, 2013.

Together with the first interim payment of 2.73 US cents per ordinary share
(2011: 2.48 US cents per ordinary share), this represents total dividends for
2012 of 17.33 US cents per ordinary share (2011: 15.07 US cents per ordinary
share), an increase of 15% in US Dollar terms.


Angus Russell, Chief Executive Officer, commented:

"It's been another strong year for Shire with 12% growth in product sales and
14% growth in Non GAAP earnings which have driven particularly strong cash
generation. While delivering strong financial results, we continue to invest in
our emerging late stage R&D pipeline.

Our ADHD portfolio is performing very well in a growing global market and we
see further growth going forward. The positive opinion received from the
European regulators for ELVANSE is a significant milestone and we're now
preparing for country launches in some of the largest markets in Europe. All
our rare disease treatments continue to grow and we saw particularly strong
performance from FIRAZYR in its first full year in the US market. We advanced
our plans for developing our Regenerative Medicine business with the
acquisition of VASCUGEL and the approval of DERMAGRAFT in Canada.

Our late stage R&D pipeline now holds the prospect of future growth from LDX
(the active ingredient in VYVANSE) in major depressive disorder, binge eating
disorder and negative symptoms of schizophrenia. Our intrathecal programs are
also progressing well as we plan the next clinical trials for Hunter CNS and
Sanfilippo A and continue to enrol MLD patients into the ongoing Phase 1/2
trial. A phase 2b study of SPD602, our iron chelating product, is underway and
headline results are expected later this year.

We've completed a number of in-licensing deals and acquisitions in 2012,
bringing us new technology platforms in rare diseases, hematology and a range
of early stage and exciting differentiated treatments.

We've put in place our leadership succession plan. Dr. Flemming Ørnskov joined
us at the beginning of January and is familiarising himself with the business
before he assumes the role of CEO at the end of April. His considerable
pharmaceutical and international experience will benefit Shire going forward.
Today we announce that Sylvie Gregoire, President of our HGT business, has
decided to leave Shire at the end of March, after five years. We're grateful
for her significant contributions to the growth of Shire through establishing
HGT as a leader in rare diseases.

Shire is in great shape, with the current business performing well, a promising
pipeline of new growth opportunities, and the strategy in place to deliver an
exciting future. As we look forward to the year ahead, we expect our financial
results to show further growth in line with current consensus earnings
expectations for 2013(1)."

Read more
Investment Tools Limited

This article which appeared in the Saturday edition of the FT on 27th October talks about investors chasing dividends. It is a good read and vindicates our stance that the only reason to invest in equities at the present time is for Dividends.

Read more
Investment Tools Limited

SHIRE SECOND QUARTER PRODUCT SALES UP 16% ON TRACK TO DELIVER DOUBLE DIGIT FULL YEAR EARNINGS GROWTH
August 1, 2012 - Shire (LSE: SHP, NASDAQ: SHPG) announces results for the three months to June 30, 2012.

Read more
Investment Tools Limited

April 26, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31,
2012.

Financial Highlights Q1 2012(1)

Product sales $1,107 million +24%

Total revenues $1,172 million +21%

Read more
Investment Tools Limited

Another strong year for Shire with revenues exceeding $4 billion for the first
time and Non GAAP EPS up 26% to $5.34.

Good 2012 earnings growth expected.

February 9, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces results for the year to December 31, 2011.

Financial Highlights Full Year 2011(1)

Product sales $3,950 million +26%

Total revenues $4,263 million +23%

Non GAAP operating income $1,357 million +27%

US GAAP operating income $1,109 million +40%

Non GAAP diluted earnings per ADS $5.34 +26%

US GAAP diluted earnings per ADS $4.53 +43%

Non GAAP cash generation $1,391 million +3%

Non GAAP free cash flow $879 million +11%

US GAAP net cash provided by operating activities $1,074 million +12%

Read more
Investment Tools Limited

Another strong year for Shire with revenues exceeding $4 billion for the first time and Non GAAP EPS up 26% to $5.34.

Good 2012 earnings growth expected.

Financial Highlights Full Year 2011(1)

Product sales $3,950 million +26%

Total revenues $4,263 million +23%

Non GAAP operating income $1,357 million +27%

US GAAP operating income $1,109 million +40%

Non GAAP diluted earnings per ADS $5.34 +26%

Read more
Investment Tools Limited

Economists and traders in the City have thought and behaved for some months as if the world is coming to an end, but that is not the message delivered by Britain's listed companies. In the past 12 months, they have paid out a record level of dividends. Given that dividends are derived from profits, it suggests this is not a story of a business world on its uppers.

Read more

Shire optimized dividend - 12 month history

Optimized dividend graph demo

Shire share price - 12 month history

You're currently viewing outdated and/or artificial data.

Try the real thing now:

Activate Free Trial